Clinical trials
Observational Breast Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
33 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Recruiting | 7 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 3 |
| AstraZeneca | 3 |
| Hoffmann-La Roche | 3 |
| Medical University of Vienna | 3 |
| Arbeitsgemeinschaft medikamentoese Tumortherapie | 2 |
| Medical University of Graz | 2 |
| Pfizer | 2 |
| Pierre Fabre Pharma GmbH | 2 |
| University Hospital, Basel, Switzerland | 2 |
| Celgene | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 33 |
| Lung Neoplasms | 6 |
| Colorectal Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Stomach Neoplasms | 3 |
| Urinary Bladder Neoplasms | 3 |
| Chemotherapy-Induced Febrile Neutropenia | 2 |
| Endocrine Gland Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Kidney Neoplasms | 2 |
Trials
Showing 1 to 25 of 33. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.